Galectin-3 in pre-B acute lymphoblastic leukemia
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Only 30-40% of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term, disease-free survival and can be considered cured. The remainder will eventually relapse and die from disease progression or other ALL-related consequences. 1, 2 Relapse most frequently originates in the bone marrow (BM), 3 where stroma protects ALL cells against drug treatment. 4 The development of drug resistance in ALL cells as occurs in vivo can be modeled by coculture of ALL cells in the presence of irradiated stromal cells during drug exposure. We have shown previously that this allows for the outgrowth of drug-insensitive leukemic cells (e.g. Zhang et al 5 ), in a process that has been named environmental-mediated drug resistance. Microarray analysis on precursor B-lineage (pre-B) ALL cells from a BCR/ABL transgenic mouse model for Ph-positive ALL undergoing environmentalmediated drug resistance showed significantly increased expression of mRNAs related to stress and inflammation. 6 Among others, we found that transcript levels of the Galectin-3 gene (Lgals3) were significantly increased upon development of resistance to the Bcr/Abl-targeted tyrosine kinase inhibitor nilotinib, and this was also seen in pre-B ALL cells isolated from the BM of BCR/ABL transgenic mice that had been treated with nilotinib for 8 days. 6 Galectin-3, a 30-kDa protein without enzymatic activity, belongs to the family of lectins, which recognize and specifically bind (mostly extracellular) carbohydrate structures. Galectin-3 has a C-terminal carbohydrate-binding domain with preference for galactose and poly-N-acetyllactosamine-modified glycans. Its N-terminal domain promotes homotypic oligomerization. Because of these domains, extracellular Galectin-3 can promote the crosslinking and lattice formation between glycan-containing molecules on the cell surface. 7 ALL cells were reported not to express Galectin-3. 8 The induction of its transcripts in the pre-B ALL cells prompted us to further examine this. We first assessed expression of Galectin-3 protein in BM samples from ALL patients using fluorescenceactivated cell sorting (FACS). Galectin-3 was clearly present in pre-B cells from BM of all four ALL patients ( Figure 1a) . Elevated serum levels of Galectin-3 were reported in some types of cancer such as metastatic colorectal cancer and melanoma. 9, 10 To evaluate circulating levels of Galectin-3 in ALL patients, plasma samples from peripheral blood and BM were collected from ALL patients, as well as controls. Interestingly, we found that plasma levels of Galectin-3 in BM from ALL patients were significantly higher than healthy controls (Po0.05) (Figure 1b) as detected by enzyme-linked immunosorbent assay. To further investigate circumstances under which Galectin-3 levels are increased, we used human patient-derived pre-B ALL cells that were passaged in NSG mice and grown ex vivo in the presence of OP9 stromal feeder cells. In this system, the ALL cells adhere to the stromal cells, migrate underneath them and return into the medium in a dynamic fashion. Notably, cells that were harvested from underneath the OP9 layer, and had thus been in direct contact with OP9 cells, expressed a high amount of Galectin-3, while cells in suspension or cells cultured without OP9 for 24 h had low expression of cell surface or intracellular Galectin-3 as measured Accepted article preview online 13 June 2013; advance online publication, 5 July 2013 Letters to the Editor by FACS (Figure 1c ). OP9 cells secrete Galectin-3 (Supplementary Figure 1) and part of the Galectin-3 detected on these ALL cells was of stromal origin (Fei F, Lim M, Groffen J, Heisterkamp N, manuscript in preparation).
As increased cellular levels of Galectin-3 are protective to several cancer cell types, 8, 11, 12 we elevated Galectin-3 levels in ALL cells by transduction of TXL2 cells with pMIG-Gal3 and control vector pMIG. As phosphorylation of serine residue 6 in Galectin-3 is needed for this protein to provide protection to BT-549 breast cancer cells against cisplatin-induced apoptosis, 12 we also compared the effect of a Gal3S6A mutant. Analysis of major signal transduction pathways in TXL2-pMIG, TXL2-pMIG-Gal3 and TXL2-pMIG-Gal3S6A cocultured with or without OP9 cells did not show major differences between these cells and their growth was also not statistically significantly different (Supplementary Figure 2) . Interestingly, compared with TXL2-pMIG and TXL2-pMIG-Gal3 cells, TXL2-pMIG-Gal3-S6A cells were more vulnerable to spontaneous apoptosis when cultured without OP9 cells over a 3-day period (Figure 2a) . Consistent with studies in other hematopoietic cell type-derived cancers including chronic myeloid leukemia, diffuse large B-cell lymphoma and multiple myeloma, 8, 13, 14 overexpression of Galectin-3 enhanced drug resistance of the TXL2 cells, to both nilotinib and vincristine, whereas TXL2-pMIG-Gal3S6A cells were more sensitive to drug treatment (Figures 2b and c) . These results demonstrate that increased intracellular Galectin-3 expression promotes resistance to drug treatment, and that abrogation of its ability to be phosphorylated on S6 results in loss of such capability.
To examine the effect of loss of endogenous Galectin-3 on ALL cells, we generated pre-B ALL cells from gal3 þ / þ and gal3 À / À BM cells by transduction with Bcr/Abl using standard procedures. 15 These cells do not require support from stroma, allowing an assessment of the function of endogenously produced Galectin-3. Transduction efficiency was confirmed by western blot (Supplementary Figure 3) . Gal3 þ / þ and gal3 À / À pre-B ALL cells had a similar proliferation rate as assessed by cell counting and cell cycle analysis (data not shown). We found that gal3 À / À cells had a specific attenuation of Erk pathway activation, as indicated by a significant decrease in pErk1/2 levels (Figure 2d ). To compare drug sensitivity, gal3 þ / þ and gal3 À / À pre-B ALL cells were treated with different concentrations of nilotinib or vincristine. As expected, nilotinib or vincristine treatment reduced viability of Bcr/Abl transformed pre-B ALL cells, but gal3 À / À pre-B ALL cells were significantly more sensitive to nilotinib or vincristine treatment than gal3 þ / þ pre-B ALL cells (Figure 2e and f) . Thus, our studies show that increased levels of Galectin-3, as found in BM plasma and pre-B ALL cells, provide protection to these leukemia cells against drug treatment. According to the WHO classification, B-cell lymphomas can be divided in several subgroups depending on their morphological and phenotypic properties. 1 Mantle cell lymphoma (MCL) accounts for 5-10% of mature B-cell neoplasms and are believed to derive from naive B cells. MCL are usually positive for CD5, CD20 and CD43, but are negative for CD10 and BCL6. CD23 is negative or weakly expressed.
1 Diagnosis of MCL is based on cytomorphology, histology, immunophenotype as well as presence of a t(11;14)(q13;q32)/IGH-CCND1 rearrangement or demonstration of cyclin D1 (CCND1) overexpression. 2 However, some cases that are considered by expression profiling or immunophenotyping to belong to the MCL entity lack the t(11;14) translocation and the CCND1 overexpression and thus are difficult to distinguish from other mature B-cell neoplasms. 3, 4 This distinction is clinically very relevant as true MCLs show an aggressive behavior, whereas many other B-cell lymphomas do not. MCL usually shows a rapid clinical evolution, poor response to conventional therapeutic regimes, frequent relapses and a median survival of 3-4 years. 5 Fortunately, new therapies seem to significantly improve the progression-free survival.
6 SOX11 is a neural transcription factor involved in tissue remodeling in embryogenesis. 7, 8 The overexpression of SOX11 has been demonstrated to be specific for MCL independent of CCND1 positivity, suggesting a diagnostic role of SOX11 expression in t(11;14)-negative MCLs.
4,9,10 SOX11 is not expressed in other lymphoid neoplasms, with the exception of lymphoblastic lymphoma, some Burkitt lymphomas and T-prolymphocytic leukemia, which are readily discriminated from MCL by standard diagnostics. 4 The prognostic role of SOX11 expression has been controversially discussed. [10] [11] [12] [13] Recently, some studies have identified a group of MCL patients with an indolent clinical course and a long survival.
14 Subsequently, the absence of SOX11 expression was described as diagnostic marker of these indolent MCLs. 11 In this study, we evaluated the applicability and usefulness of SOX11 expression as a diagnostic marker for differentiation of mature B-cell neoplasms and to determine its impact on outcome.
We analyzed 219 patients with mature B-cell neoplasms that were diagnosed by cytomorphology, immunophenotyping, cytogenetics and fluorescence in situ hybridization, and based on these methods categorized into t(11;14)-positive MCL (n ¼ 100), 
